Minerva Neurosciences, Inc. (NERV)

Minerva Neurosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	21.36	40.91	36.09	60.76	25.36
Cash & Short-Term Investments	21.36	40.91	36.09	60.76	25.36
Cash Growth	-47.79%	13.35%	-40.59%	139.60%	-44.70%
Other Receivables	-	-	3.12	-	-
Receivables	-	-	3.12	-	-
Prepaid Expenses	0.81	0.99	0.85	1.35	1.98
Restricted Cash	0.1	0.1	0.1	0.1	0.1
Total Current Assets	22.27	42	40.16	62.2	27.44
Property, Plant & Equipment	0.01	0.01	0.02	-	0.1
Goodwill	14.87	14.87	14.87	14.87	14.87
Other Intangible Assets	-	0.02	0.04	0.05	-
Long-Term Deferred Charges	-	-	-	-	15.2
Other Long-Term Assets	-	-	-	-	0.01
Total Assets	37.14	56.9	55.09	77.12	57.63
Accounts Payable	1.61	1.81	0.97	1.85	1
Accrued Expenses	1.23	1.54	0.41	0.97	2.05
Current Portion of Leases	-	-	-	-	0.11
Total Current Liabilities	2.84	3.34	1.38	2.82	3.16
Long-Term Debt	60	82.02	73.73	66.33	-
Long-Term Deferred Tax Liabilities	-	-	-	-	1.8
Total Liabilities	62.84	85.36	75.11	69.15	4.96
Common Stock	0	0	0	0	0
Additional Paid-In Capital	369.68	368.36	346.79	342.68	337.45
Retained Earnings	-395.38	-396.82	-366.81	-334.7	-284.8
Shareholders' Equity	-25.69	-28.46	-20.02	7.98	52.66
Total Liabilities & Equity	37.14	56.9	55.09	77.12	57.63
Total Debt	60	82.02	73.73	66.33	0.11
Net Cash (Debt)	-38.64	-41.1	-37.64	-5.57	25.25
Net Cash Growth	-	-	-	-	-44.60%
Net Cash Per Share	-5.10	-6.32	-7.05	-1.04	4.94
Filing Date Shares Outstanding	6.99	6.99	5.34	5.34	5.34
Total Common Shares Outstanding	6.99	6.99	5.34	5.34	5.34
Working Capital	19.43	38.66	38.78	59.38	24.28
Book Value Per Share	-3.67	-4.07	-3.75	1.49	9.86
Tangible Book Value	-40.56	-43.34	-34.94	-6.94	37.79
Tangible Book Value Per Share	-5.80	-6.20	-6.54	-1.30	7.08

Updated Feb 25, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q